scispace - formally typeset
W

Winfried März

Researcher at Synlab Group

Publications -  304
Citations -  33146

Winfried März is an academic researcher from Synlab Group. The author has contributed to research in topics: Coronary artery disease & Cholesterol. The author has an hindex of 63, co-authored 288 publications receiving 25902 citations. Previous affiliations of Winfried März include Medical University of Graz.

Papers
More filters
Journal ArticleDOI

Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Simon I. Hay, +803 more
- 16 Sep 2017 - 
TL;DR: At a global level, DALYs and HALE continue to show improvements and the importance of continued health interventions, which has changed in most locations in pace with the gross domestic product per person, education, and family planning.

Genetic studies of body mass index yield new insights for obesity biology

Adam E. Locke, +481 more
TL;DR: This paper conducted a genome-wide association study and meta-analysis of body mass index (BMI), a measure commonly used to define obesity and assess adiposity, in up to 339,224 individuals.
Journal ArticleDOI

Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Ashkan Afshin, +131 more
- 11 May 2019 - 
TL;DR: The consumption of major foods and nutrients across 195 countries is evaluated to quantify the impact of their suboptimal intake on NCD mortality and morbidity and to inform implementation of evidence-based dietary interventions.
Journal ArticleDOI

Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Boris Bikbov, +221 more
- 29 Feb 2020 - 
TL;DR: The burden of CKD was much higher than expected for the level of development, whereas the disease burden in western, eastern, and central sub-Saharan Africa, east Asia, south Asia, central and eastern Europe, Australasia, and western Europe was lower than expected.
Journal ArticleDOI

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

TL;DR: A multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo found the median level of low-density lipoprotein cholesterol was reduced.